成人疫苗

首頁 > 疫苗接種 > 成人疫苗

預防帶狀疱疹(生蛇)疫苗, 成人疫苗
預防帶狀疱疹(生蛇)疫苗, 成人疫苗
預防帶狀疱疹(生蛇)疫苗
Shingles (Herpes Zoster) Vaccine

「帶狀疱疹」俗稱「生蛇」,是由水痘病毒引起的疾病。患者身上會出現一種令人痛楚而呈帶狀的紅疹,並有水泡。凡感染過水痘的人都有機會「生蛇」,如病毒上眼或入耳,什至有機會引致眼盲或耳聾。據估計約有三分之一的人一生中可能罹患帶狀疱疹,常見於年長者或兒童中。


95%的成年人均具有「生蛇」的風險,而且50歲後的風險大大增加;三份一人將在其一生中「生蛇」,更可以是非常痛楚的!帶狀疱疹疫苗可降低50-80歲接種者一半的得病機率,也有助於降低帶狀疱疹後的神經痛,或再發時的嚴重度。 查詢帶狀疱疹疫苗價錢及預約接種蛇針第二代疫苗,聯絡香港仁和體檢中心。18歲或以上高危人士接種前建議先諮詢醫生。

Herpes zoster, also known as shingles, is caused by the same virus that causes varicella (chickenpox). Herpes zoster is a disease pervaded by painful red spots that appears in band-like pattern with blisters. Anyone who has had chickenpox has a chance of getting the disease. Almost 1 out of 3 people will develop shingles in their lifetime and it is more common in older adults or children. In some cases, getting the virus in eyes and ears can lead to blindness or deafness.

95% of adults are at risk of getting herpes zoster, and the risk increases significantly after the age of 50. 1 out of 3 people will develop the disease in their lifetime. While the suffering can be very painful, vaccination can reduce the chance of getting the disease by half in people aged 50-80. It can also help reduce the severity of nerve pain when having shingles or when it recurs. For enquiry of herpes zoster vaccine price and booking of 2nd generation shingles vaccine, please contact re:HEALTH.

四價流行性感冒疫苗
四價流行性感冒疫苗
Quadrivalent Seasonal Influenza Vaccine

秋冬季是流感高峰期,免疫力較低人士很容易感染流感。不想被新冠疫情和流感同時影響?最有效方法就是接種流感疫苗,及早做好預防!四價流感疫苗* 限時優惠$240 (原價 $450) ,請致電或 WhatsApp 預約! WhatsApp快線查詢及預約:(+852) 6324 5948 到店後可直接享會員價,同時會為您安排專業顧問跟進,請於Whatsapp留下姓名及理想預約日期,於一個工作天內回覆。

Autumn and winter are the peak seasons for influenza and people with low immunity are susceptible to the disease. If you do not want to be infected with COVID-19 and influenza at the same time, the most effective way is to get vaccinated against influenza and to take precautions! Quadrivalent Seasonal Influenza Vaccine* is now in limited-time offer at a discounted price $240 (original price $450). Please call or WhatsApp (+852) 6324 5948 for enquiries and appointments. Enjoy our membership discount and consultancy services upon your arrival. Please leave your name and availability via WhatsApp. We will respond within a business day.


全新B型腦膜炎雙球菌疫苗_thumbnail.jpg
全新 B型腦膜炎雙球菌疫苗

由腦膜炎雙球菌感染之流行性腦膜炎在海外國家例如英國、美國和澳洲的發病率係遠高於香港!這種致命性傳染病在香港每年約有 10-20 名確診個案,死亡率約 10-20%。如選擇移民或海外留學,最好於出發前先諮詢醫生並且考慮接種疫苗預防。而初生嬰兒與幼童屬於較高危一族,都建議接種腦膜炎雙球菌疫苗,加強預防能力!

全新 B型腦膜炎雙球菌疫苗是唯一批準可供10歲以下兒童接種的B型腦膜炎雙球菌疫苗,獲美國FDA及歐盟EMA批準,含有4種抗體,保護更全面!

title_icon.jpg
新冠疫苗接種服務 – 科興
COVID-19 Vaccination Service - Sinovac

仁和體檢為認可疫苗接種中心,現提供科興新冠疫苗接種服務,市民可提前14天於網上預約系統預約。

Contact us via WhatsApp: (+852) 6324 5948 for inquiries and appointments. Please leave your name and availability via WhatsApp. We will respond within a business day.

title_icon.jpg
新冠疫苗接種服務 - 復必泰
COVID-19 Vaccination Service - BioNTech

仁和體檢為認可疫苗接種中心,現提供復必泰新冠疫苗接種服務,市民可提前14天於網上預約系統預約。

Contact us via WhatsApp: (+852) 6324 5948 for inquiries and appointments. Please leave your name and availability via WhatsApp. We will respond within a business day.

新冠疫苗,接種疫苗,健康評估
新冠疫苗,接種疫苗,健康評估
新冠疫苗接種前健康評估
COVID-19 Pre-vaccination Health Assessment

衞生防護中心的指引中列出患有嚴重慢性疾病的人士需延遲接種新冠疫苗,直至病況受控為止,其中包括高血壓、糖尿病及高血脂人士。很多市民平時沒有作定期健康檢查,可能早已患上慢性疾病而不自知,家族有慢性病史的更屬高危一族。醫思健康現正推出「新冠疫苗接種前健康評估」,為有意接種疫苗人士作健康風險評估,並由醫生講解報告。請致電或 WhatsApp 了解更多。

Many citizens do not have regular health checks, unaware of the fact that they may have suffered from chronic diseases, including hypertension, diabetes and hyperlipidaemia. Nevertheless, family history of chronic illnesses makes them a higher risk group.     re:HEALTH is now offering COVID-19 Pre-vaccination Health Assessment and Pre-vaccination Blood Allergy Test for potential vaccine recipients, who will receive a health assessment report explained by the doctor.

13價肺炎結合疫苗, 成人疫苗
13價肺炎結合疫苗, 成人疫苗
13價肺炎結合疫苗
13-valent Pneumococcal Conjugate Vaccine (PCV13)

13價肺炎鏈球菌疫苗有效預防侵入性肺炎球菌病及肺炎球菌引致的非侵入性肺炎。另一方面,臨床研究顯示 23 價疫苗可預防侵入性肺炎球菌病,但對於預防肺炎球菌引致的非侵入性肺炎的效能未如理想。不過,值得注意的是,23 價肺炎球菌多醣疫苗包含更多種血清型,理論上提供了額外的保護。

PCV13 is effective against both invasive pneumococcal disease and non-invasive pneumococcal pneumonia. While clinical studies indicated that 23vPPV is generally effective in preventing invasive pneumococcal disease, its efficacy against non-invasive pneumococcal pneumonia is suboptimal. Nevertheless, it is worth noting that 23vPPV covers more serotypes and theoretically offers extra protection.